Overview: Fibrin Degradation Products (FDP) TestIntroduction: The Fibrin Degradation Products (FDP) Test measures fibrinogen degradation products to diagnose clotting disorders, causing bleeding or thrombosis. Following 2023 ASH guidelines, it uses an immunoassay for high sensitivity, aiding in coagulation screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in hematology for patients with suspected clotting disorders.
Other Names: FDP Assay, Fibrin Breakdown Test.
FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic accuracy.
Historical Milestone: FDP testing began in the 1970s with coagulation research. Immunoassays emerged in the 1980s, and by the 2000s, high-sensitivity assays improved accuracy.
Purpose: Diagnoses clotting disorders, guides anticoagulant therapy, and monitors FDP levels in patients with bleeding or thrombosis.
Test Parameters: 1. Fibrinogen Degradation Products
Pretest Condition: No fasting required. Collect plasma at any time. Report symptoms like bleeding or thrombosis, and list medications like anticoagulants.
Specimen: 2-4 mL plasma (NaCit). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document bleeding, thrombosis, or history of clotting disorders (e.g., DIC). Include current medications, especially anticoagulants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for anticoagulant therapy.
Procedural Considerations: Uses an immunoassay to measure FDP levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Anticoagulants or improper storage can affect results. Hemolysis may reduce accuracy.
Clinical Significance: Elevated FDP levels suggest clotting disorders like DIC, prompting therapy. Normal levels may require further testing.
Specialist Consultation: Consult a hematologist for result interpretation.
Additional Supporting Tests: D-dimer, PT/INR, or fibrinogen levels to confirm clotting disorders.
Test Limitations: Non-specific elevations may occur in non-clotting conditions. Results require clinical correlation.
References: ASH Coagulation Guidelines, 2023; Journal of Thrombosis and Haemostasis, Weitz JI, 2022.
